01 — At a Glance
The Pharma Darling That Broke Its Own China. For Now.
- 52-Week High / Low₹2,727 / ₹2,012
- 9M FY26 Revenue₹10,835 Cr
- 9M FY26 PAT₹1,379 Cr
- Q3 FY26 EPS₹9.90
- Annualised EPS (Q3×4)₹39.60
- Book Value₹370
- Price to Book5.91x
- Dividend Yield0.05%
- Debt / Equity0.55x
- Profit Growth (TTM)-9%
Auditor’s Opening Note: Mankind Pharma posted ₹3,567 crore Q3 revenue (+11.5% YoY), but PAT at ₹414 crore shows a messy story. The company is India’s #1 by prescriptions, #2 by volume in IPM, yet profit margins compressed due to R&D spend, labour code adoption, and a brutal internal “transformation” that management admits went wrong. The 9M growth is 18.7% revenue but -9% profit (TTM). The stock trades at 48.6x P/E — over 75% premium to industry median. Chronic therapies are growing 15%+. Acute therapies are in ICU. BSV acquisition for ₹13,768 crore is still being digested. Fasten your seatbelt.
02 — Introduction
The Prescription Powerhouse That Forgot How to Count
Mankind Pharma. Founded in 1995. #1 in prescription volume for eight consecutive years. Over ₹500 crore in branded formulations revenue. A field force of 18,000+. Presence in 50+ acute and chronic therapeutic areas across India. Four consumer healthcare brands ranked #1 in their categories. It’s the kind of company that gets featured in textbooks on how to build a distribution moat.
So what went wrong? On the February 2026 concall, management did something rare for Indian pharma CEOs: it admitted fault. CEO Rajeev Juneja described a “major kind of transformation” over the last 12–18 months involving 20–25% of the field force being cycled through (fired, quit, or reassigned). The stated reason? Cultural integration gone sideways during the shift toward a chronic-focused model. The honest quote: “We overestimated our power of executing.” Translation: We broke morale, good people left, relationship-dependent acute segments tanked, and now we’re rebuilding.
Chronic therapies are doing great — cardiovascular +16.7% YoY in Q3, anti-diabetes +14.4% YoY. But acute — the bread-and-butter for relationship-driven prescription sales — is still limping. The stock response? Up marginally, then down. The market priced in execution risk, and rightfully so. The question now is whether the disruption is behind or ahead.
In the meantime, the company spent ₹13,768 crore acquiring the women’s health portfolio from Bharat Serums and Vaccines (BSV). One of the largest pharma M&A deals in Indian history. The thesis: access to specialty, women’s health, and critical care therapies. The execution risk: integrating a new business while fixing your core engine. All of this while balancing a P/E of 48.6x, which prices in perfection.
Management Concall (Feb 2026): “There are no targets. We believe only in daily sales… not weekly… prescription is sale. That’s all. Rest all is farce.” — Rajeev Juneja. Translation: Mankind operates like a startup in a controlled chaos mode. It works until it doesn’t.
03 — Business Model: Rx Pills, Consumer Condoms, Export Dreams
Where Does the Cash Actually Come From?
Mankind’s business is deceptively simple: make pharma formulations, sell them to doctors and patients, scale distribution. But the portfolio depth is what separates it from competitors. Think of it as a department store for pills. Cardiovascular (15% of revenue), anti-infectives (14%), gynaecology (10%), gastro (10%), anti-diabetics (8%), and a long tail of specialty plays. The company has 23 brands worth ₹100+ crores and 49 brands worth ₹50+ crores. These are fortress positions — not monopolies, but close to it in their niches.
Consumer healthcare is where Mankind prints money on brand recognition alone. Manforce (condoms, #1 with 28% market share), Prega News (pregnancy kits, 87% market share), Unwanted-72 (emergency contraceptive, 68% market share), and Gas-O-Fast (antacids). These are household names. The Q3 consumer healthcare revenue was 7% of total, but EBITDA margins are fat — 70%+. The strategy post-IPO is to move this up the stack through modern trade and e-commerce, which is now 13% of OTC sales (up from 10% last year).
Exports are the emerging lever. 9M FY26 exports: ₹1,503 crore (+51% YoY). The US is the main market, with 42 products in the portfolio. Management is being disciplined — no trophy acquisitions, only niche molecules with EBITDA potential. Udaipur facility just got EU GMP certification, which opens doors in Europe and regulated markets. By 2028–2029, management expects ROW commercialization to add meaningful revenue.
Domestic Rx80%of 9M Revenue
Consumer HC7%High margin
Exports14%51% YoY growth
BSV (New)~5%Post-acquisition
Distribution Moat: Mankind has 16,000+ field force, 13,000+ stockists, 500,000+ doctors in network, and 75 CFAs. PCPM (per candidate per month) improved to ₹7.2 lakhs (Dec 2025 TTM) from ₹6.5 lakhs (Mar 2025). This is relationship capital. When those relationships break due to field-force churn, acute segments crater. Which is exactly what happened.
💬 How much of Mankind’s premium valuation is baked into the assumption that the acute recovery will be “gradual”? What if it stays broken?
04 — Financials Overview: Q3 FY26 Snapshot
The Good, The Bad, and The Really Messy Exceptional Items
Result type: Quarterly Results (Q3 FY26) | Q3 EPS: ₹9.90 | Annualised EPS (Q3×4): ₹39.60 | 9M PAT: ₹1,378.7 Cr
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 3,567 | 3,199 | 3,697 | +11.5% | -3.5% |
| Operating Profit | 919 | 816 | 921 | +12.6% | -0.2% |
| OPM % | 26% | 26% | 25% | Flat | +100 bps |
| PAT (Reported) | 414 | 385 | 520 | +7.5% | -20.4% |
| EPS (₹) | 9.90 | 9.22 | 12.39 | +7.4% | -20.1% |
The Fine Print Explainer: Q3 PAT looks OK at +7.5% YoY, but don’t celebrate yet. Adjusted EBITDA margin fell 170 bps YoY due to (a) R&D spend up 70 bps to 2.9% of revenue, (b) labour code adoption costs, and (c) employee cost inflation from field-force “transformation” — the polite word for mass disruption. Reported EBITDA margin was 22.9% vs adjusted 25.9% due to exceptional items: labour code changes, stamp duty on BSV slump sale, and impairment of a ₹13 crore Hyderabad land parcel. The stock gets hit on profit growth rates, especially when the commentary is “we broke things internally and are rebuilding.” P/E of 48.6x prices in near-perfection from here.
05 — Valuation: Fair Value Range
What’s This Company Actually Worth? (Accounting for the Chaos)
Join 10,000+ investors who read this every week.
